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Summary
During normal aging and in chronic diabetes the excessive accumulation of reactive glucose-
protein or glucose-lipid adducts known as advanced glycosylation endproducts (AGES) has been
shown to induce tissue dysfunction, in part through interaction with AGE-specific receptors
on monocyte/macrophages and othercells. Recognizing that circulating lymphocytes trafficking
through tissues interact with tissue AGES, we searched for the expression of AGE-binding sites
on peripheral blood T lymphocytes. Resting rat and human T cells bound 125I-AGE-albumin
with an affinity of 7.8 x 101 M-1, whereas, after stimulation with phytohemagglutinin (PHA)
for 48 h, binding affinity increased to 5.8 x 108 M -1 . Flow cytometric analysis of resting rat
T cells using polyclonal antibodies raised against rat liver AGE-binding proteins (p60 and p90)
revealed the constitutive expression of both immunoreactivities. The number of resting CD4'
and CD8+ T cells positive for anti-p60 antibody binding (34.2 and 58.5%, respectively)
increased to 92 and 90% of cells after 48-h stimulation with PHA. Exposure of PHA-activated
T lymphocytes to AGE-albumin enhanced expression of interferon 'y (IFN-'y) mRNA 10-fold
and induced greater elaboration of the mature protein than did exposure to unmodified protein
or PHA treatment alone. These data indicate that T cells contain an inducible system of surface
receptors for AGE-modified proteins, and that receptor occupancy is linked to lymphokine
production. This T cell AGE-receptor system might serve to target lymphocytes to AGE-rich
tissues and involve them in the regulation of tissue homeostasis either by assisting in macrophage-
dependent clearance of AGE-proteins, or by exerting direct antiproliferative action on mesenchymal
cells. Under conditions of excessive AGE-protein and AGE lipid accumulation (e.g., aging and
diabetes), enhanced production of AGE-induced IFN--y may accelerate immune responses that
contribute to tissue injury.
Deducing sugars such as glucose can react nonenzymati-
cally with protein amino groups in a time- and con-
centration-dependent manner to form a family of complex
structureswhich are referred to as advanced glycosylation end-
products (AGE)' (1-3). The excessive deposition of these
covalent adducts on various body proteins has been shown
to contribute to the development of the complications of aging
and diabetes by both direct chemical (covalent crosslink for-
mation), and cell surface receptor-mediated pathways (3) .
' Abbreviations used in this paper: AGE, advanced glycosylation endproduct;
FBS, fetal bovine serum; f-BSA, formaldehyde-modified BSA; FFI, 2-furoyl-
4-(5)-2-furanyl)-1-H-imidazole; HSA, human serum albumin; NaBH4,
sodium borohydride; TPA, O-Tetradecanoylphorbol 13-acetate.
Cells of the monocyte/macrophage lineage were the first
found to display a surface receptor system mediating the
binding and internalization ofAGE-modified macromolecules.
These receptors are structurally and functionally distinct from
other known macrophage scavenger receptors (4, 5). AGE-
specific affinity labeling of cell surface proteins in the murine
macrophage-like cell line RAW 264.7 revealed a single AGE-
associated band at -90 kD (6, 7). Subsequently, two AGE-
binding proteins, one of 60 and the other of 90 kD were
isolated from rat liver member preparations and partially se-
quenced (8) .
Rat liver p60 and p90 were used to raise Abs, which rec-
ognized surface determinants on rat monocytes and macro-
phages (8). The same Abs inhibit AGE binding and neutralize
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(9) and on murine mesangial cells (10), suggesting that the
AGE-receptor system involves proteins with highly conserved
domains. In addition to exhibiting significant transendothelial
migratory activity toward AGE-modified matrix in vitro and
in vivo (11), AGE-stimulated monocyte/macrophages are in-
duced to secrete several cytokines and growth factors, such
as TNF-a, IL-1R, platelet-derived growth factor (PDGF),
and insulin-like growth factor (IGF)-IA (9, 11, 12). These
coordinate activities suggest that the macrophage AGE-
receptor, mediating the selective removal ofAGES, may also
be involved in growth regulatory activities within tissues.
Other cell types, e.g., human endothelial cells (13-15),
mesangialcells (10, 16), and fibroblasts (17), have been shown
to contain AGE-specific binding proteins that are linked to
diverse functions. For instance, the exposure of vascular en-
dothelialcells in vitro to increasing levels ofAGE-proteinresults
in disruption of normal barrier function and enhancement
ofcell-associated procoagulant activity (13), whereas the in-
teraction of AGE ligands with therenal mesangialcell AGE-
receptorsis associated with increased matrix protein synthesis
(10, 16). Based on thedifferent bindingspecificities andfunc-
tional characteristics of the cell type-specific AGE-receptors
identified thus far, it remains unclear whether these mole-
cules arestructurally related to themacrophage AGE-receptor
proteins. Nevertheless, the identification of an AGE-receptor
system has introduced a new mechanism by which macro-
phages can participate in both the maintenance of normal
extracellular matrix, and in certain pathological processes,
such diabetic vascular disease and atherosclerosis (18).
AGE-receptor-mediated macrophage activation maybe one
mechanism by which immune cell activation may promote
atherogenesis (19). In fact, several lines of evidence have sug-
gested that other immune cellssuch as lymphocytesmay play
an important role in this progressive disorder which has been
recently attributed to achronicinflammatory process. Tlym-
phocytes, which are ubiquitously present in inflammatory
states, are also abundant in the vessel wall during the early
stages of atherogenesis (19, 20). Cells of both the CD4+,
and CD8+ phenotype are present and they express surface
antigens that suggest an activated state (21). The stimulus
for the recruitment and activation of such T cells remains
unknown, as is their specific function in this slowly evolving
process.
Given the spontaneous and progressive accumulation of
AGES within the tissues of diabetics, and in particular, the
vascular matrix, we postulated that lymphocytes mayexpress
AGE-specific receptors which allow them to interact with
tissue AGES and contribute to the immune activation and
effector activities within the vessel wall. We describe here
the presence of two such AGE-binding proteins on rat and
human T cells. These appear antigenically related to thep60
andp90AGE-receptor polypeptides present on monocyte/mac-
rophages and can be upregulated upon stimulation with
mitogens. AGE-receptor-ligand interaction on thesurfaceof
activated lymphocytes results in the synthesis and secretion
of IFN-y.
2166
￿
T Cell AGE-Receptors
Materials and Methods
Chemicals and Reagents.
￿
Humanserum albumin (HSA), BSA
(Fraction V, lowendotoxin), andTriton X-100were purchasedfrom
Boehringer Mannheim Biochemicals (Indianapolis, IN). Bovine
RNaseandglucose 6-phosphate were purchased from Sigma Chem-
ical Co. (St. Louis, MO). Sodium "'I (sp act 10 mCi/100Al) was
obtained from New England Nuclear (Boston, MA). Nitrocellu-
lose membranes were from Schleicher &Schuell (Keene, NH). The
chemically synthesized model AGE, 2-(2-furoyl)-4(5)-(2-furanyl)-
1H-imidazole-hexanoic acid (FFI-HA) was provided by Dr. Peter
Ulrich (Picower Institute). PHA, O-tetradecanoylphorbol 13-acetate
(TPA) (Sigma Chemical Co.), andionomycin, were purchased from
Calbiochem-Novabiochem Corp. (La Jolla, CA). Avian anti-rat
polyclonal Abs raised against rat liver AGE-binding proteins p60
and p90 were prepared as described (8). Monoclonal anti-rat-
CD5+, -CD4+, -CD8' were purchased from Bioproducts for
Science, Inc. (Indianapolis, IN).
Preparation and Radiolabeling ofLigands.
￿
AGE-bovine or HSA
andAGE-RNasewere madeby incubating each protein with 0.5 M
glucose at 37'C for 6 wk in 10 mM PBS, pH 7.4, in the presence
of protease inhibitors and antibiotics as previously described (4,
8). Unincorporated glucose was removed by dialysis against PBS.
AGE andunmodified proteins were purified over heparin-Sepharose
CL6B (Pharmacia LKB, Piscataway, NJ) to remove contaminants
(10) . Endotoxin content in all samples was measured by Limulus
amoebocyte lysate assay (E-toxate, SigmaChemical Co.) andfound
to be <0.2 ng/ml. AGE contentwas assessed by an AGE-specific
ELISA (22). AGE-BSA contained -7.0 AGE U/mg; AGE-HSA,
8.3 U/mg; and AGE-RNase, 5.7 AGE U/mg. Unmodified BSA
and HSA contained 0.02 AGE U/mg each.
To examine the effect of reducing early glycosylation product
on ligand binding, AGE-BSAwas incubatedwith 200-molarexcess
NaBH4 (Sigma Chemical Co.) for 10 min at 4°C and for 1 h at
room temperature (16). The reduced AGE-BSA was then dialyzed
against PBS. The chemically defined model AGE, FFI-HA, was
synthesized and linked to BSA with 100 mM carbodiimide as de-
scribed previously (23). Formaldehyde-modified BSA (f-BSA) was
prepared as described (5). In brief, BSA was incubated in 0.1 M
sodium carbonatebuffer (pH 10) with 0.33 Mformaldehyde at 37°C
for 5 h, followed by extensive dialysis against PBS.
AGE-ligands were iodinated with carrier-free tz'I by the Iodo-
genmethod (Bio-Rad Laboratories, Cambridge, MA)(24). Samples
were dialyzed against PBS until >95% of radioactivity was TCA
precipitable.
Cell Preparation. Heparinized blood was drawn from male
Sprague-Dawley rats (200-300 g) bycardiac puncture. Heparinized
humanblood wasdrawn from healthy volunteers. 3ml of dextran
T-500 (Pharmacia Fine Chemical, Piscataway, NJ) were added to
10 ml of blood and the mixtures were allowed to sediment for45
min. The PBMC-containing fraction was separated on a Ficoll-
Paquegradient (25) and plated with medium containing 10% FBS
for 30 min at 37°C to allow monocytes to adhere. Nonadherent
cellswere collected andpassed through anylonwool column (Poly-
science, Inc., Warrington, PA) (26) . Collected cells were >95%
CD3' T cells, as determined by flow cytometry, using PE-
conjugated Leu-4 (anti-CD3) (Becton Dickinson & Co., Moun-
tain View, CA). Highly purified humanT cells were isolated from
normal PBMC with a sequential four-step procedureas described
(26).
Membrane Preparation.
￿
Purified ratandhumanperipheral blood
T cells were washed in PBS. After centrifugation, cells were dis-
rupted with a tight Dounce homogenizer, in a solution of PBScontaining 3% EDTA and protease inhibitors (2 mM PMSF, 10
,ug/ml aprotinin, 5ng/mlpepstatin, 1 mM benzamidine). Thenu-
clear and organelle-enriched fractions were removedby centrifuga-
tion at 1,000g for 10 min. Membranes then were isolated from
the supernatant by centrifugation at 10,000 g for 20 min at 4°C.
Theresulting enriched membrane fraction was solubilized in PBS
containing 1% Triton X-100, andprotease inhibitors as stated above.
Theprotein concentration wasdetermined by themethod ofBrad-
ford (27). This material then was used forligand andWesternblot
studies.
Binding Studies.
￿
Radioligand binding studies were performed
on rat or human T cells in 6-well plates (106 cells/well). The
studieswere performedin 0.1 ml ofbindingmedium (RPMI 1640,
25 mM Hepes, pH 7.2, 3 mg/ml BSA, 0.02% NaN3) in thepres-
ence of 1III-AGE-BSA (sp act 7 x 10' cpm/ng) for 3 h at 4°C.
At the end of the incubation, cells were layered on 0.3 ml fetal
bovine serum (FBS) in a0.4-mlpolypropylenetube andcentrifuged
at 9,000 rpmfor 90 s. Each tube was cutjust above the cell pellet,
and radioactivity was measured by Gamma Trac 1193 (Tm Ana-
lytic, ElkGrove Village, IL). Nonspecific binding of 1251-AGE-BSA
was determined in parallel incubations by adding 100-fold excess
of unlabeled AGE-BSA. Protein concentrationwas determined by
the method of Bradford (27). Specific binding was defined as the
difference between totalbinding (cells incubatedwith radioligand
alone) and nonspecific binding (cells incubated with radiolabeled
ligand plus 100-fold excess unlabeledligand). Scatchardanalysis of
thedata was performedto determinethe binding affinity constant
and the receptor number as described previously (16, 28).
Uptake andDegradation.
￿
Tcell uptake anddegradation of AGE-
BSA was performedaccording to previously described procedures
(4,16) with minormodifications. Briefly, cellswere plated in 6-well
plates in RPMI containing 20% FBS andinsulin. Intracellular ac-
cumulation of radioactive ligand was assessed by incubating cells
with various concentrations of 1211-AGE-BSA, in the presence and
absenceof 100-fold excess ofunlabeledAGE-BSA, for6hat 37°C.
After suspending the cells on FBS and centrifuging for 90 s, the
amount of cell-associatedradioactivity wasdetermined as described
above. Specific uptake wasdefinedby the same criteria as used for
the binding studies. Degradation was determined by measuring
TCAsoluble radioactivity in the aspirated medium.
Ligand Blotting.
￿
Human PBLs or highly purified T cells were
collected either unstimulated or after stimulation with PHA (2
jig/ml) plusTPA(1 ng/ml) or ionomycin(1 NAM) plus TPA(1 ng/ml)
for 48 h. T cells (107) cell membrane preparations were electro-
phoresed on a nonreducing SDS-PAGE (12%), and then electro-
blotted onto anitrocellulose filter, as previously described(8).After
blocking for 1 h in a solution of PBS containing 1.5% BSA and
0.1% Triton X-100, the nitrocellulose filter wasprobed with 125I-
AGE-BSAin thepresence of 100-fold excess ofeither BSAor AGE-
BSA. Theblot was washed three times with PBS and exposed to
Kodak XAR5 film at -80°C.
Flow Cytometric Analysis.
￿
Double color cell staining was per-
formed by incubating one million cells with biotinylated anti-60
kD, anti-90 kD, or preimmuneantisera andFITC-conjugatedanti-
CD4, anti-CD5, and anti-CD8 Absat saturating concentrations,
as primary Abs for 30 min at 4°C. For secondary staining, cells
were washed in staining buffer (PBS, 3% FBS, 0.1% NaN3) and
then incubated with avidin-PE (Becton Dickinson & Co.). Back-
ground fluorescence was determined by staining the cells with a
relevant isotypic control Ab, e.g., biotinylated chicken IgG. Cells
were analyzed using aFACScan® (BectonDickinson& Co.). The
data were analyzed by Paint-A-Gate software (Hewlett-Packard,
Arondale, CA).
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RNA Preparation and PCR Assay for Human IFN-y
mRNA. Purified human T cells (2.0 x 106/well) were cultured
in RPMI 1640 supplemented with 10% FBS, 5 x 10-5 M2-ME,
100U/ml penicillin, and 100IAg/ml streptomycin for 48 h, in the
presence or absence of PHA (1-10 Etg/ml). Cells then were trans-
ferred to 24-well plates coated with AGE-HSA or HSA (at 5
wg/cm2), prepared as described (10) . After 6 h, T cells were
washed by PBS and total RNA was extracted as described (9) by
using RNAzol (Cinna/Biotex, Friendswood, TX), andresuspended
in 20 1zI of diethylpyrocarbonate (DEPC)-treated water. 1 t~g of
total RNA was incubated with 10 P1 of 5x RT buffer (250 mM
Tris-HCL (pH 8.3), 375 mM KCl, 15 mM MgC1z), 200 Uof mu-
rine mammary leukemia virus (M-MLV) reverse transcriptase
(GIBCO BRL, Gaithersburg, MD), 1 mM dNTPs (Perkin-Elmer
Corp., Norwalk, CT), 1 IAg/ml BSA (GIBCO BRL), and oligo
(dT)12-1s (Pharmacia LKB), for 1 h at 37°C. 5 Al of cDNA was
amplifiedin 0.5 ml GeneAmpreaction tubes (Perkin-Elmer Corp.)
in the presence of 200 nM final concentration of 5' (5'-ATG-
AAATATACAAGTTATATCTTGGCTTT3') and3' (5'-CATGCT
CTTCGACCTCGAAACAGCAT3') primers, 200 NAM dNTPs,
0.5 UTaqpolymerase (Perkin-Elmer Corp.), and PCRbuffer con-
taining 10 mM Tris-HCI, pH 8.3, 50 mM KCI, 1.5 MM MgC12,
and0.001% gelatinin afinalvolume of80 IA PCRwasperformed
in aDNAthermalcycler (Perkin-Elmer Corp.) for 35 cycles: 1min
denaturation at 92°C, 1 min annealing at 55°C, and 1minexten-
sion at 72°C. 15 ul of reaction mixture was electrophoresed in
2% agarose containing 0.5 IAg/ml ethidium bromide. A 123-bp
DNAladder was used as amolecularweight marker (GIBCO BRL).
AssayforIFN-ySecretion.
￿
Aftera48-h prestimulation with PHA
(1-10 ug/ml), purified human T cells (6 x 106) were plated on
AGE-HSA or HSAcoated wells (5 Ntg/cm2) with RPMI con-
taining FBS (10%) for 24 h. The supernatants were collected and
IFN-yconcentrationwas determined using theInterTest-y ELISA
kit (Genzyme, Cambridge, MA).
Results
AGE-binding on Ratand Human TCells.
￿
Freshlyisolated
rat PBL lymphocytes were tested for AGE-specific binding
as described above (4, 16). With increased concentrations of
1251-AGE-BSA, specific binding increased in a saturable
fashion (Fig. 1A). Scatchardanalysis of bindingdata revealed
a single linear regression line, indicating asingle set ofbinding
sites on resting T cells (12.2 x 105 sites/cell) (Fig. 1 A, inset)
and a binding affinity of 7.78 x 101 M-1. After a 48-h in-
cubation with PHA alone (10 Fig/ml), the specific binding
for AGE-modified albumin was markedly enhanced, and the
binding affinity (K,) increased to 5.8 x 108 M-1 , whereas
the receptor number increased to 84.6 x 105 sites/cell (Fig.
1 B, and its inset).
The specificity of AGE binding to T cells was tested in
competition experiments usingeither an AGE-modified pro-
tein distinct from albumin (AGE-RNase), or BSA modified
either by the syntheticAGE modelcompound FFI (FFI-BSA),
or by formaldehyde (f-BSA). Although AGE-RNase com-
peted effectively for binding against 1251-AGE-BSA (Fig. 1
C, a), neither FFI-BSA nor f-BSA were inhibitory (Fig. 1
C, c, andd). Also,unmodified HSA(Fig. 1 C,f) and mannan,
a polysaccharide recognized by a distinct class of mannose-
specific lymphocyte receptors (29) failed to compete forAGE-
bindingwhen addedin concentrations up to 300 Wg/ml (Fig.2168
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radiolabeled AGE-BSA was tested by extending incubations
with the ligand for up to 6 h at 37°C . No significant changes
were noted in either cell-associated or in TCA-soluble radio-
activity of the media (data not shown) .
To determine whether the T cell AGE-binding sites con-
tained epitopes related to those found on monocyte/macro-
phages, 1251-AGE-BSA binding inhibition experiments were
carried out using Abs raised against two AGE-binding pro-
teins, p60 and p90, isolated from rat liver (8) . These Abs
have been shown to inhibit binding of AGE-ligands on rat
monocyte/macrophages (8) . Each Ab was used separately as
well as in combination (Fig . 2) . In the presence of a constant
amount of 1251-AGE-BSA as ligand and with increasing con-
centrations of either anti-p60 or anti-p90 Ab as competitor,
significant inhibition of AGE-ligand binding was observed
(up to 90%), and the combination of both Abs at a concen-
tration of 2,ug/ml yielded a>95% inhibition ofAGE-ligand
binding . In contrast, no inhibition of binding was observed
when a preimmune chicken IgG was used as a control (Fig. 2) .
Flow Cytometry ofRat T Lymphocytes.
￿
Two major sub-
groups ofT lymphocytes, CD4+ and CD8+ were examined
for surface expression of epitopes crossreactive with existing
antimacrophage AGE-receptor Abs, using flow cytometry.
One million cells were stained with biotinylated anti-p60 or
anti-p90 and avidin-PE, FITC-conjugated monoclonal anti-rat
CD5, CD4, and CD8 Abs . As shown in Fig. 3, using resting
cells, 36% of CD5+ cells stained positively with anti-p60
Ab, whereas 35% ofcD4+ and 58% ofCD8+ cells stained
positively with the sameAb . No immunoreactivity was re-
vealedwhen nonspecific IgG was used as a control (data not
shown) . After stimulation with PHA/TPA for 48 h, the ex-
pression of the p60 molecule was upregulated significantly
(Fig. 3) . Similarly, 18, 24, and 25% ofCD5+, CD4+, and
CD8+ T cells, respectively, stained with anti-p90 Abs. After
Antibody concentration (1tg/ml)
Inhibition of 1251-AGE-BSA binding on rat peripheral T cell
chicken anti-p60 and anti-p90 Abs . Cells were incubated with
gand (25 RAg/ml) in the presence of each Ab added alone or in
n, or in preimmune serum . Data are expressed as cpm of
bound AGE-BSA in the presence of the respective Ab and rep-
mean of duplicate experiments, each performed in triplicate .
6000
5000
Figure 1 . Binding of 1251-AGE-BSA to resting (A) andPHAstimulated
4000
rat peripheral bloodT cells (B) . PurifiedT cells were incubated with var-
ious concentrations ofiodinated AGE-BSA for 2 h at 4°C, in the presence E
or absence of 100-fold excess unlabeled AGE-BSA . Specific binding was a 3000
obtained by subtracting nonspecific binding from total binding . (Insets) U
Scatchard plots for the specific binding data (Bound, pM, Free, nM) . (C)
Competitive inhibition of 1251-AGE-BSA (25 /tg/ml) binding to rat T cells 2000
by different ligands added at a 100-fold excess : (a) AGE-ribonuclease, (b)
NaBH 4-reduced AGE-BSA, (c) FFI-BSA, (d) f-BSA, (e) mannan (300 1000
pg/ml, (f) unmodified HSA . Data are representative of five experiments,
each performed in triplicate.
0
1 C, e) . NaBH4-reduced AGE-BSA competed equally well Figure 2 .
with unreducedAGE-BSA for binding by T cells, ruling out surface by
the possibility that the observed binding activity was due
the radiol
to early glycosylation products (4, 5) (Fig. 1 C, b) . combinatiospecifically
In additional studies, the ability of T cells to internalize resent theactivation, no enhancement in the expression ofp90 was noted
on these cells despite stimulation (data not shown) .
Ligand Blotfrom Human T Cells.
￿
The presence ofAGE-
binding proteins on the surface ofhuman T cells was further
explored using either unfractionated PBLs or highly purified
T cell membranes, before or after a 48-h activation by
PHA/TPA or TPA/ionomycin. Membrane components were
separated by nonreducingSDS-PAGE (12%), then transferred
onto nitrocellulose membranes and blotted with the ligand
1251-AGE-BSA. As shown in Fig. 4, an AGE-binding pro-
tein with an apparent molecular mass of -55-60 kD was
readily visible in membranes of activated PBLs (Fig . 4, lane
B), but not of resting PBLs (Fig . 4, lane A) . The presence
of 100-fold excess unlabeled AGE-BSA effectively inhibited
the binding of radiolabeled AGE-BSA to the N55-kD pro-
tein band, indicating binding specificity (Fig. 4, lane C) . Simi-
larly, an AGE-binding protein with identical mobility was
identified in membranes prepared from activated (Fig. 4, lanes
Figure 4 .
￿
Ligand blot analysis of resting (A and D) and activated (B,
C, E, F, and G) human PBL or highly purifiedT cells. Membrane pro-
teins from 10 7 cells were used either untreated (resting) or after activa-
tion with PHA or ionomycin plus TPA, were electrophoresed on a non-
reducing SDS-PAGE (12%), and electroblotted on nitrocellulose (NC) filter,
and probed with 12SI-AGE-BSA, in the presence (C and G) or absence
(A, B, D, E, andF) of 100-fold excess AGE/BSA . Data are representative
of three identical experiments.
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Figure 3 .
￿
Demonstration by flow cytometry
ofexpression ofcross-reactivity with anti-AGE-
proteins on purified rat peripheralT cells. Rep-
resentative experiment using anti-p60 AB.
(A-C) RestingT cells. (D-F)T cells prestimu-
lated with PHA (2 kg/ml) + TPA (1 Fcg/ml)
for 48 h . Double color cell staining was per-
formed using biotinylated chicken anti-p60 (5
ttg/ml), or FITC-conjugated anti-CD4, anti-
CD5, anti-CDS as primary Abs, followed by
avidin-PE.
E and F), but not from resting, purifiedT cells (Fig . 4, lane
D) .The method ofT cell activation did not appear to influence
the level of induction of the 55-kD AGE-binding protein,
as both combinations of either PHA/TPA (Fig. 4, lane E)
or TPA/ionomycin (Fig . 4, lane F) yielded identical results.
The addition of excess AGE-BSA completely abrogated the
appearance of the 55-kD protein (Fig. 4, lane G) .
IFN-y mRNA Expression Is Induced byAGE-BSA inPHA-
stimulatedHuman T Cells. cDNA amplification experiments
showed that purified humanT cells can be induced byAGE-
modified HSA to express mRNA for IFN-y . As shown in
Fig . 5, lane C, IFN-y transcripts were readily detected in
lymphocytes pretreated with PHA for 48 h and then exposed
toAGE-HSA coated dishes for 6 h . Similar treatment ofPHA-
Figure 5 .
￿
Detection of IFN- .y mRNA in PHA-activated human pe-
ripheral bloodT cells bycDNA amplification . After prestimulation with
PHA, cells were incubated on AGE-HSA or HSA coated wells for 6 h.
Data are representative ofthree identical experiments. LaneA,PHA alone;
laneB, AGE-HSA alone; lane C, PHA plus AGE-HSA ; and lane D, PHA
plus HSA.stimulated T cells with unmodified HSA failed to upregulate
IFN-y mRNA, (Fig. 5, lane D), indicating that elevated levels
were a specific response to AGE-modified protein. AGE-HSA
alone did not elicit detectable levels of IFNy mRNA (Fig.
5, lane B), nor did PHA alone under the conditions used
(Fig. 5, lane A). To ensure that the PCR product generated
using IFN-y primers originated from IFN-y mRNA, the
isolated fragment was digested with the restriction enzymes
BamHI and DraI. After amplification, isolation, and diges-
tion of the full-length fragment with the respective restric-
tion enzymes, individual fragment sizeswere assessed by gel
electrophoresis, which yielded fragments of the expected sizes
(data not shown).
IFN-y Secretion Is Induced by AGE-BSA in PHA-stimulated
T Cells. Since induction of mRNA is not always followed
by the secretion of the corresponding protein, the secretion
of IFN-y protein in PHA-activated human T cells in response
to AGE-HSA was determined. As shown in Fig. 6, a significant
dose-dependent release of IFN-y into the medium occurred
when cells stimulated with PHA for 48 h were exposed to
an AGE-HSA-coated surface for 6 h. PHA stimulation alone
or PHA followed by the addition of unmodified HSA failed
to elicit this response.
Discussion
The results presented in this report indicate that human
and rat peripheralblood T lymphocytes express surface binding
sites specific for molecules modified by AGEs. The evidence
E
tr
tL
z
AGE-HSA
HSA
PHA
Ligand Concentration (pg/rnl)
Figure 6.
￿
Secretion ofIFN-y into mediumby human peripheralPHA-
activated T cells. After prestimulation with PHA, cells were incubated
on AGE-HSA (solid bars) or HSA-coated wells (dotted bars) for 24 h, as
described. IFN-y concentration was determined in the supernatants by
ELISA. (Open bars) Cells exposed to PHA alone. Data are expressed as
ng/ml ofIFN-y and represent the mean ± SEM oftriplicate determinations.
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is severalfold. Resting T lymphocytes from both species bind
the in vitro-generated ligand AGE-albumin in a saturable
fashion, with a binding affinity (K,) of 7.7 x 107 M - ' at
resting state, which rises to 5.8 x 108 M -1 after stimula-
tion with PHA. binding of AGEs by intact T cells is specific
for the AGE moiety, since an AGE-modified protein distinct
from albumin, AGE-RNase, competed for binding whereas
unmodified albumin or albumin modified by other agents
(e.g., formaldehyde) did not. Radiolabeled AGE-ligandbinding
was inhibited by polyclonal Abs, raised against two AGE-
receptor peptides isolated from rat liver, p60, and p90 kD
(8), and FRCS® analysis confirmed the presence of two cor-
respondingcell surface epitopes, distributed primarily among
cD4+ and CD8+ cells. Ligand blotting studies on mem-
braneproteins from resting and stimulated T cellsconfirmed
the presence of at least one major AGE-Binding membrane
protein with an estimated molecular mass of 55-60 kD.
Although by ligand blotting no AGE-binding band corre-
sponding to 90 kD was observed, the presence of a second
binding protein on the cell surface could be inferred from
the ligand-binding inhibition experiments using the anti-p90
Ab, in conjunction with the flow cytometry data which in-
dicated a lack of responsiveness to PHA-stimulation com-
pared with that obtained with the anti-p60 Ab. A similar
discrepancy in binding activity between intact cells and
detergent-processed, nitrocellulose-immobilized membranes
was observed previously by the corresponding 90-kD AGE-
binding protein isolated from rat liver membranes (8). This
protein, although active on intact cells, consistently lost AGE-
binding activity once transferred to nitrocellulose (8). From
the available evidence, it is tempting to speculate that, in a
manner analogous to the monocytes/macrophagesystem (8),
only the 55-kD protein is capable ofbinding AGEs, whereas
an additional one or more membrane structures may be im-
portant for the stabilization of the ligand-55 kD interaction
on the cell surface. This is supported by the ability of the
anti-p90 Ab to inhibit this interaction.
Binding studies showed that prestimulation of resting T
cells with PHA significantly upregulated both binding affinity
and the number ofAGE binding sites per cell. This was fur-
ther evidenced by FACS® analysis and radioligand blotting
using different lymphocyte activators. The enhanced AGE-
receptor activity, when evaluated flow cytometrically appeared
attributable mostly to the increased expression of the AGE-
binding protein that was recognized by the anti-p60 Ab, since
the putative membrane protein recognized by the anti-p90
Ab remained unchanged upon stimulation. The actual com-
position and the dynamic nature of the cooperation of the
AGE-receptors on T cells remains conjectural until approaches
are used that allow the determination of the size of native
receptors without the denaturingconditions employed here.
Binding of AGEs to the T cell surface is not followed by
internalization or degradation of the bound ligand to a dis-
cernible degree. However, once activated by an independent
stimulant, binding markedly enhances synthesis and release
of IFN-y, a response not achieved even when usingmaximal
doses of PHA alone. In this regard, the function of this TCR
system is distinct from that of the AGE-receptors present onmonocyte/macrophages (8), an important function ofwhich
is the endocytosis and destruction of AGE-modified mole-
cules and cells (4, 5, 30). Previous studies have demonstrated
that AGES can induce macrophage activation, followed by
cytokine (TNF-oz, IL-1/.) (12) and growth factor (PDGF, IGF-
IA) release (9, 11) possibly contributing to the growth-
promoting pattern involved in the turnover of extracellular
matrix. In contrast, AGES alone could not prompt T cell
activation and lymphokine production, suggestingthat, not
unlike other TCRs, including the two subunits of the IL-2
receptor (31), AGE-receptors are constitutively expressed, but
are not functional until the T cells are activated. In order
for AGE-ligands to induce an increase in the message for,
as well as the secretion of IFN-y T cells required a 48-h pres-
timulation. The inability of AGE-HSA to prompt lymphokine
release in the absence of a primary stimulus suggests an in-
ducible system subject to regulation by other lymphocyte-
specific antigens or activators. The possibility that the re-
lease of IFN-y is due to a specific subset of cells, e.g., NK
cells cannot be ruled out from these studies, although this
is unlikely given the magnitude of the response obtained from
preparations containing >95% T cells.
The observation that T cells, like macrophages have receptors
for AGE-modified proteins suggests a mechanism for com-
munication and cooperation between these two cell systems
during tissue homeostasis and repair. The precise steps to-
ward this interaction remain largely obscure. Extracellular
matrix components are known to form spontaneously AGEs
at levels increasing with age and with diabetes (1-3). In both
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